Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494444 | 1.00 | GPR119 (0.41) | GPR119IRAK4JAK2JAK1EGLN2 | |
| SCHEMBL13339881 | 0.84 | GPR119 (0.39) | GPR119IRAK4JAK2JAK1EGLN2 | |
| SCHEMBL3494641 | 0.82 | PKM (0.39) | GPR119SCD5 | |
| SCHEMBL3491570 | 0.81 | GPR119 (0.40) | GPR119IRAK4JAK2JAK1EGLN2 | |
| SCHEMBL3491568 | 0.81 | GPR119 (0.40) | GPR119IRAK4JAK2JAK1EGLN2 | |
| SCHEMBL3493790 | 0.80 | SCD5 (0.38) | GPR119SCD5 | |
| SCHEMBL3491818 | 0.76 | GPR119 (0.44) | GPR119IRAK4JAK2JAK1EGLN2 | |
| SCHEMBL3491817 | 0.76 | GPR119 (0.44) | GPR119IRAK4JAK2JAK1EGLN2 | |
| SCHEMBL3492047 | 0.68 | KMT2A (0.55) | GPR119 | |
| SCHEMBL309439 | 0.68 | KMT2A (0.55) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | GPR119 25/4885IRAK4 2443/4885JAK2 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.